From: A cancer disparities curriculum in a hematology/oncology fellowship program
POST-CURRICULUM SURVEY | |||||
---|---|---|---|---|---|
Strongly Disagree | Disagree | Neutral | Agree | Strongly Agree | |
The presentations were well organized | 0 (0) | 0 (0) | 1 (7.1) | 6 (42.9) | 7 (50) |
The information presented was relevant to my practice | 0 (0) | 0 (0) | 2 (14.2) | 9 (64.3) | 3 (21.3) |
Overall expectations were met | 0 (0) | 0 (0) | 2 (14.2) | 4 (28.6) | 8 (57.1) |
The information presented is useful for training as a Hematologist/Oncologist | 0 (0) | 0 (0) | 2 (14.2) | 4 (28.6) | 8 (57.1) |
The discussions improved my insight into disparities in Hematology/Oncology | 0 (0) | 0 (0) | 2 (14.2) | 4 (28.6) | 8 (57.1) |
Poor | Fair | Good | Very Good | Excellent | |
Overall clinical training in disparities in healthcare | 0 (0) | 0 (0) | 3 (21.4) | 9 (64.3) | 2 (15) |
Understanding of racial/ethical disparities in Hematology/Oncology | 0 (0) | 1 (7.15) | 4 (28.6) | 6 (42.9) | 3 (21.4) |
Understanding of gender-identity and sexual orientation in Hematology/Oncology | 0 (0) | 2 (14.3) | 4(28.6) | 5 (35.7) | 3 (21.4) |
Understanding of language barriers in Hematology/Oncology | 0 (0) | 1 (7.1) | 4(28.6) | 4(28.6) | 5 (35.7) |
Disparities in clinical trials and access to novel therapies | 0 (0) | 1 (7.1) | 4(28.6) | 6 (42.9) | 3 (21.4) |
Journal articles | Panel discussions | Modules | Podcasts | ||
What was your favorite session or part of the curriculum? | 1 (6.67%) | 12 (80%) | 1 (6.67%) | 1 (6.67%) | |
Yes | No | ||||
Do you feel you need more training in healthcare disparities? | 10 (71%) | 4 (29%) | |||
Yes | No | ||||
After this focus on health disparities, do you plan to incorporate health disparities into a future research or clinical project? | 11 (79%) | 1 (7%) | |||
Yes | No | ||||
Would you recommend this curriculum to future hematology/oncology fellows? | 10 (71%) | 0 (0%) | |||
Yes | No | ||||
Do you recommend that the fellowship program have a formal health disparities curriculum? | 11 (79%) | 3 (21%) |